[1] Liu, H., Dicksved, J., et al. (2014) Heat Shock Proteins: Intestinal Gatekeepers That Are Influenced by Dietary Components and the Gut Microbiota. Pathogens, 1, 187-210.
https://doi.org/10.3390/pathogens3010187
[2] Ritossa, F. (1962) A New Puffing Pattern Induced by Temperature Shock and DNP Indrosophila. Experientia, 12, 571-573.
https://doi.org/10.1007/BF02172188
[3] Young, J.C., et al. (2001) Hsp90: A Specialized but Essential Protein-Folding Tool. Journal of Cell Biology, 2, 267-273.
https://doi.org/10.1083/jcb.200104079
[4] Wu, S.H., Cheng, J. and Zheng, Y.J. (2005) Relationship between Heat Shock Protein Family and Liver Cancer. World Journal of Chinese Digestion, No. 14, 87-92.
[5] Ali, M.M.U., et al. (2006) Crystal Structure of an Hsp90-Nucleotide-p23/Sbal Closed Chaperone Complex. Nature, 7087, 1013-1017.
https://doi.org/10.1038/nature04716
[6] Hellenkamp, B., Philipp, W. and Florian, K. (2017) Multidomain Structure and Correlated Dynamics Determined by Self-Consistent FRET Networks. Nature Methods, 14, 174-180.
https://doi.org/10.1038/nmeth.4081
[7] Prodromou, C., et al. (1997) Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone. Cell, 1, 65-75.
https://doi.org/10.1016/S0092-8674(00)80314-1
[8] Cheng, G. and Hu, W.X. (2009) Biological Characteristics of Heat Shock Protein 90. Chemistry of Life, 5, 687-690.
[9] Andrija, F. and Pierre, G. (2013) Proteomic Data from Human Cell Cultures Refine Mechanisms of Chaperone-Mediated Protein Homeostasis. Cell Stress Chaperones, 5, 591-605.
https://doi.org/10.1007/s12192-013-0413-3
[10] Verba, K.A., et al. (2016) Atomic Structure of Hsp90-Cdc37-Cdk4 Reveals That Hsp90 Traps and Stabilizes an Unfolded Kinase. Science, 6293, 1542-1547.
https://doi.org/10.1126/science.aaf5023
[11] Chen, Y., Wang, X. and Cao, C. (2017) Inhibition of HSP90 Sensitizes a Novel Raf/ERK Dual Inhibitor CY-9d in Triple-Negative Breast Cancer Cells. Oncotarget, 61, 104193-104205.
https://doi.org/10.18632/oncotarget.22119
[12] Stivarou, T., et al. (2016) Targeting Highly Expressed Extracellular HSP90 in Breast Cancer Stem Cells Inhibits Tumor Growth in Vitro and in Vivo. Cancer Biology & Therapy, 8, 799-812.
https://doi.org/10.1080/15384047.2016.1195041
[13] Lee, C.H., et al. (2012) Inhibition of Heat Shock Protein (Hsp) 27 Potentiates the Suppressive Effect of Hsp90 Inhibitors in Targeting Breast Cancer Stem-Like Cells. Biochimie, 6, 1382-1389.
https://doi.org/10.1016/j.biochi.2012.02.034
[14] Rong, B.X. and Yang, S.Y. (2018) Molecular Mechanism and Targeted Therapy of Hsp90 Involved in Lung Cancer: New Discoveries and Developments (Review). International Journal of Oncology, 2, 321-336.
https://doi.org/10.3892/ijo.2017.4214
[15] Cedres, S., Felip, E. and Cruz, C. (2018) Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient with a Germline BRCA1 Mutation. Journal of the National Cancer Institute, 8, 914-917.
https://doi.org/10.1093/jnci/djy012
[16] Sun, Y., Huang, Y.H. and Huang, F.Y. (2018) 3’-epi-12beta-hydroxyfro-side, a New Cardenolide, Induces Cytoprotective Autophagy via Blocking the Hsp90/Akt/mTOR Axis in Lung Cancer Cells. Theranostics, 7, 2044-2060.
https://doi.org/10.7150/thno.23304
[17] Dong, P.F. and Deng (2017) Clinical Significance of Serum Heat Shock Protein 90 α in Patients with Non-Small Cell Lung Cancer. Chinese General Medicine, 19, 2354-2357.
[18] Sun, P.P. and Chen (2017) Research Progress of EGFR Targeted Therapy for Non-Small Cell Lung Cancer. International Respiratory Journal, 2, 148-151.
[19] da Silva, V.C. and Ramos, C.H. (2012) The Network Interaction of the Human Cytosolic 90 kDa Heat Shock Protein Hsp90: A Target for Cancer Therapeutics. Journal of Proteomics, 10, 2790-2802.
https://doi.org/10.1016/j.jprot.2011.12.028
[20] White, P.T., et al. (2016) Novel HSP90 Inhibitors Effectively Target Functions of Thyroid Cancer Stem Cell Preventing Migration and Invasion. Surgery, 1, 142-151.
https://doi.org/10.1016/j.surg.2015.07.050
[21] Lin, S.F., et al. (2017) Efficacy of an HSP90 Inhibitor, Ganetespib, in Preclinical Thyroid Cancer Models. Oncotarget, 25, 41294-41304.
https://doi.org/10.18632/oncotarget.17180
[22] Su, Y.H., et al. (2015) Targeting of Multiple Oncogenic Signaling Pathways by Hsp90 Inhibitor Alone or in Combination with Berberine for Treatment of Colorectal Cancer. Biochim Biophys Acta, 1853, 2261-2272.
https://doi.org/10.1016/j.bbamcr.2015.05.012
[23] Ma, W., et al. (2018) The Progress of Heat Shock Protein 90 in the Study of Gastric Cancer. Medical Science Journals of Central South China, 1, 98-112.
[24] Cheng, Z.J., et al. (2015) Risk Factors and Management for Early and Late Intrahepatic Recurrence of Solitary Hepatocellular Carcinoma after Curative Resection. HPB, 5, 422-427.
https://doi.org/10.1111/hpb.12367
[25] Sohn, W., et al. (2014) HBV DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-Related Hepatocellular Carcinoma. Annals of Surgical Oncology, 7, 2429-2435.
https://doi.org/10.1245/s10434-014-3621-x
[26] Sun, S.P., et al. (2003) Sun Level, the Expression and Significance of HSP90 α in Hepatocellular Carcinoma. Chinese Journal of Basic and Clinical General Surgery, No. 3, 243-245.
[27] Li, H., et al. (2014) The Significance of Heat Shock Protein 90 α Expression in HBV-Related Hepatocellular Carcinoma. Journal of Guangzhou Medical University, 42, 21-24.
[28] Fu, Y., et al. (2017) Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-Scale, and Multicenter Clinical Trial. EBioMedicine, 24, 56-63.
https://doi.org/10.1016/j.ebiom.2017.09.007
[29] Ochiana, S.O., Taldone, T. and Chiosis, G. (2014) Designing Drugs against Hsp90 for Cancer Therapy. In: Houry, W.A., Ed., the Molecular Chaperones Interaction Networks in Protein Folding and Degradation, Interactomics and Systems Biology, Vol. 1, Springer, Berlin, 151-183.
https://doi.org/10.1007/978-1-4939-1130-1_7
[30] Patel, H.J., et al. (2011) Advances in the Discovery and Development of Heat-Shock Protein 90 Inhibitors for Cancer Treatment. Expert Opinion on Drug Discovery, 6, 559-587.
https://doi.org/10.1517/17460441.2011.563296
[31] Supko, J.G., et al. (1995) Preclinical Pharmacologic Evaluation of Geldanamycin as an Antitumor Agent. Cancer Chemotherapy and Pharmacology, 36, 305-315.
https://doi.org/10.1007/BF00689048
[32] Soga, S., et al. (2003) Development of Radicicol Analogues. Current Cancer Drug Targets, 3, 359-369.
https://doi.org/10.2174/1568009033481859
[33] Banerji, U., et al. (2005) Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino 17-Demethoxygeldanamycin in Patients with Advanced Malignancies. Journal of Clinical Oncology, 23, 4152-4161.
https://doi.org/10.1200/JCO.2005.00.612
[34] Lancet, J.E., et al. (2010) Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (KOS-1022, 17-DMAG) Administered Intravenously Twice Weekly to Patients with Acute Myeloid Leukemia. Leukemia, 24, 699-705.
https://doi.org/10.1038/leu.2009.292
[35] Kummar, S., et al. (2010) Phase I Trial of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-D.M.A.G.), a Heat Shock Protein Inhibitor, Administered Twice Weekly in Patients with Advanced Malignancies. European Journal of Cancer, 46, 340-347.
https://doi.org/10.1016/j.ejca.2009.10.026
[36] Brough, P.A., et al. (2008) 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer. Journal of Medicinal Chemistry, 51, 196-218.
https://doi.org/10.1021/jm701018h
[37] Shiotsu, Y., et al. (2000) Novel Oxime Derivatives of Radicicol Induce Erythroid Differentiation Associated with Preferential G(1) Phase Accumulation against Chronic Myelogenous Leukemia Cells through Destabilization of Bcr-Abl with Hsp90 Complex. Blood, 96, 2284-2291.
https://doi.org/10.1182/blood.V96.6.2284
[38] Chatterjee, S. and Burns, T.F. (2017) Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach. International Journal of Molecular Sciences, 18, 1978.
https://doi.org/10.3390/ijms18091978
[39] Augello, G., et al. (2019) Targeting HSP90 with the Small Molecule Inhibitor AUY922 (Luminespib) as a Treatment Strategy against Hepatocellular Carcinoma. International Journal of Cancer, 144, 2613-2624.
https://doi.org/10.1002/ijc.31963